Vistagen therapeutics stock.

VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) …Wall Street Stock Market & Finance report, prediction for the future: You'll find the VistaGen Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data VistaGen Therapeutics's VTGN shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. We ...

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PMVistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.(NASDAQ: VTGN) Vistagen Therapeutics currently has 27,023,038 outstanding shares. With Vistagen Therapeutics stock trading at $2.57 per share, the total value ...

Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...

Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.VistaGen Therapeutics stock news, updates & related news. Find out why VistaGen Therapeutics's (VTGN) news sentiment is 12.96% more negative in relation to ...Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.

April 06, 2023 at 08:34 am EDT. Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for …

Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise ...

Aug 15, 2023 · 3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ... According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00.Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ...

Mar 25, 2020 · Going forward, subject to the terms and conditions of the agreement, VistaGen will have the option, but not any obligation, to sell to LPC up to an additional $10.0 million of its common stock over the next 24 months. VistaGen plans to use proceeds from the initial sale of common stock and subsequent sales under the agreement, if any, for ... Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the …3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and …VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of …Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …Find the latest Vistagen Therapeutics, Inc. (VTGN) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.

Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...

According to 2 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 526.87% from the latest price.The average price target represents a 123.64% change from the last price of $3.13.Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. VistaGen Therapeutics, Inc. Common Stock (VTGN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data ...Vistagen Therapeutics, Inc. Stock price Equities VTGN US92840H4002 Biotechnology & Medical Research Market Closed - Nasdaq. Other stock markets. …The current Vistagen Therapeutics [ VTGN] share price is $3.38. The Score for VTGN is 29, which is 42% below its historic median score of 50, and infers higher risk than normal. VTGN is currently trading in the 20-30% percentile range relative to …Feb 7, 2023 · Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022.

Biotech Firm Pops 677% on Social Anxiety Spray Trial Success. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits ...

Press Releases. Year. All Years. Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results. Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific …

Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing ...William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on …VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. We ...As of February 7, 2023, the Company had 219,326,526 shares of common stock outstanding, which reflects the issuance of approximately 12.4 million unregistered shares of common stock associated with the Pherin Pharmaceuticals transaction. Conference Call. ... VISTAGEN THERAPEUTICS, INC.Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit. If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...Discover Vistagen Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... CEO & Director exercised options to buy US$120k worth of stock. May 17. VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety …VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ...Instagram:https://instagram. iwm futuresbest cannabis stocksnapchat financialswho is cathie wood 5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... airplane insurance quotegoogl stock price target 3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ... best forex broker in usa mt4 This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to …Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.